COMPANY

Nanoscope Therapeutics

HQ: Dallas, TX source · nanostherapeutics.com ↗

Keywords: Stargardt disease ophthalmology Retinitis Pigmentosa Retinal Degeneration Retinal Diseases Retinitis Eye Diseases Hereditary Eye Diseases Retinal Dystrophies Retinal Disease Macular Degeneration Geographic Atrophy Retinal Dystrophy Gene Therapy Product-MCO-010 Gene Therapy product:vMCO-I Gene Therapy-vMCO-010

Location: Dallas, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

Jan 28, 2025 Trial start —: A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT source ↗
Dec 8, 2023 Trial start —: Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study source ↗
Oct 19, 2023 Trial start —: Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study source ↗
Jul 14, 2023 Trial start —: A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection source ↗
Apr 25, 2023 Trial start —: Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT source ↗
Jul 5, 2022 Trial start Phase 2: Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease source ↗
Jul 13, 2021 Trial start Phase 2: Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] source ↗
Oct 23, 2019 Trial start Phase 1/Phase 2: Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa source ↗

Upcoming milestones

2027-05 (ESTIMATED) · · Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study · NCT06048185
2027-07 (ESTIMATED) · · Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study · NCT06162585

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT05921162	A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection	Not listed	Enrolling by invitation	Jul 14, 2023	2025-05 (estimated)
NCT06048185	Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study	Not listed	Active, not recruiting	Oct 19, 2023	2027-05 (estimated)
NCT06162585	Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study	Not listed	Active, not recruiting	Dec 8, 2023	2027-07 (estimated)
NCT06805474	A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT	Not listed	Recruiting	Jan 28, 2025	May 20, 2025 (estimated)
NCT04945772	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]	Phase 2	Completed	Jul 13, 2021	Feb 27, 2023 (actual)
NCT05820100	Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT	Not listed	Completed	Apr 25, 2023	Oct 17, 2023 (actual)
NCT05417126	Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease	Phase 2	Completed	Jul 5, 2022	Aug 2, 2023 (actual)
NCT04919473	Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa	Phase 1/Phase 2	Completed	Oct 23, 2019	Feb 25, 2020 (actual)